Amylin Pharmaceuticals: Diabetes and Beyond

Posted: 11 Jun 2009

See all articles by Richard G. Hamermesh

Richard G. Hamermesh

affiliation not provided to SSRN

Rachel Gordon

Harvard University - Business School (HBS)

Date Written: March 26, 2009

Abstract

Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time the company has a second drug, Byetta, in its pipeline. Graham must decide how to manage the company's limited resources while also finalizing another deal that has huge future potential. Graham knows that Amylin's immediate success depends on its ability to commercialize its products but its long-term success depends on replenishing its pipeline. Can the company do it all successfully?

JEL Classification: G31, A20

Suggested Citation

Hamermesh, Richard G. and Gordon, Rachel, Amylin Pharmaceuticals: Diabetes and Beyond (March 26, 2009). HBS Case No. 809011, Available at SSRN: https://ssrn.com/abstract=1416764

Richard G. Hamermesh (Contact Author)

affiliation not provided to SSRN ( email )

Rachel Gordon

Harvard University - Business School (HBS) ( email )

Soldiers Field Road
Morgan 270C
Boston, MA 02163
United States

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
524
PlumX Metrics